Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/53617 |
Resumo: | Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil. |
| id |
CRUZ_0a716509cbfacd73d653191eedb7fe5a |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/53617 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Cunha, Danielle de Brito eFrederico, Ana Beatriz TeixeiraAzamor, TamirisMelgaço, Juliana GilNeves, Patricia Cristina da CostaAno Bom, Ana Paula DinisTilli, Tatiana MartinsMissailidis, Sotiris2022-07-03T14:08:35Z2022-07-03T14:08:35Z2022CUNHA, Danielle de Brito e etal. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. Pharmaceuticals, v. 15, 575, p. 1 - 21, 2022.1999-4923https://www.arca.fiocruz.br/handle/icict/5361710.3390/ph15050575engMDPIMedicamento personalizadoentrega de siRNAEmpresa biofarmacêuticaDesempenho de siRNA em ensaios clínicosPersonalized medicinesiRNA deliveryBiopharmaceutical companyPerformance of siRNA in clinical trialsBiotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Druginfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleFundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Plataforma de Oncologia Translacional. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Investigação Cardiovascular. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil.The depth and versatility of siRNA technologies enable their use in disease targets that are undruggable by small molecules or that seek to achieve a refined turn-off of the genes for any therapeutic area. Major extracellular barriers are enzymatic degradation of siRNAs by serum endonucleases and RNAases, renal clearance of the siRNA delivery system, the impermeability of biological membranes for siRNA, activation of the immune system, plasma protein sequestration, and capillary endothelium crossing. To overcome the intrinsic difficulties of the use of siRNA molecules, therapeutic applications require nanometric delivery carriers aiming to protect double-strands and deliver molecules to target cells. This review discusses the history of siRNAs, siRNA design, and delivery strategies, with a focus on progress made regarding siRNA molecules in clinical trials and how siRNA has become a valuable asset for biopharmaceutical companies.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/53617/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALTatianaTilli_PatriciaNeves_etal_IOC_2022.pdfTatianaTilli_PatriciaNeves_etal_IOC_2022.pdfapplication/pdf2534821https://www.arca.fiocruz.br/bitstream/icict/53617/2/TatianaTilli_PatriciaNeves_etal_IOC_2022.pdf901d3e7d624c48db8bab366b0ca418faMD52icict/536172022-07-03 11:08:35.141oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-07-03T14:08:35Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| title |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| spellingShingle |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug Cunha, Danielle de Brito e Medicamento personalizado entrega de siRNA Empresa biofarmacêutica Desempenho de siRNA em ensaios clínicos Personalized medicine siRNA delivery Biopharmaceutical company Performance of siRNA in clinical trials |
| title_short |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| title_full |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| title_fullStr |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| title_full_unstemmed |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| title_sort |
Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug |
| author |
Cunha, Danielle de Brito e |
| author_facet |
Cunha, Danielle de Brito e Frederico, Ana Beatriz Teixeira Azamor, Tamiris Melgaço, Juliana Gil Neves, Patricia Cristina da Costa Ano Bom, Ana Paula Dinis Tilli, Tatiana Martins Missailidis, Sotiris |
| author_role |
author |
| author2 |
Frederico, Ana Beatriz Teixeira Azamor, Tamiris Melgaço, Juliana Gil Neves, Patricia Cristina da Costa Ano Bom, Ana Paula Dinis Tilli, Tatiana Martins Missailidis, Sotiris |
| author2_role |
author author author author author author author |
| dc.contributor.author.fl_str_mv |
Cunha, Danielle de Brito e Frederico, Ana Beatriz Teixeira Azamor, Tamiris Melgaço, Juliana Gil Neves, Patricia Cristina da Costa Ano Bom, Ana Paula Dinis Tilli, Tatiana Martins Missailidis, Sotiris |
| dc.subject.other.pt_BR.fl_str_mv |
Medicamento personalizado entrega de siRNA Empresa biofarmacêutica Desempenho de siRNA em ensaios clínicos |
| topic |
Medicamento personalizado entrega de siRNA Empresa biofarmacêutica Desempenho de siRNA em ensaios clínicos Personalized medicine siRNA delivery Biopharmaceutical company Performance of siRNA in clinical trials |
| dc.subject.en.pt_BR.fl_str_mv |
Personalized medicine siRNA delivery Biopharmaceutical company Performance of siRNA in clinical trials |
| description |
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos. Laboratório de Tecnologia Imunológica. Rio de jJaneiro, RJ, Brasil. |
| publishDate |
2022 |
| dc.date.accessioned.fl_str_mv |
2022-07-03T14:08:35Z |
| dc.date.available.fl_str_mv |
2022-07-03T14:08:35Z |
| dc.date.issued.fl_str_mv |
2022 |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
CUNHA, Danielle de Brito e etal. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. Pharmaceuticals, v. 15, 575, p. 1 - 21, 2022. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/53617 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1999-4923 |
| dc.identifier.doi.none.fl_str_mv |
10.3390/ph15050575 |
| identifier_str_mv |
CUNHA, Danielle de Brito e etal. Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. Pharmaceuticals, v. 15, 575, p. 1 - 21, 2022. 1999-4923 10.3390/ph15050575 |
| url |
https://www.arca.fiocruz.br/handle/icict/53617 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/53617/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/53617/2/TatianaTilli_PatriciaNeves_etal_IOC_2022.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 901d3e7d624c48db8bab366b0ca418fa |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1798325097125117952 |